Unanswered questions in frontline CLL treatment

Acalabrutinib and Venetoclax VS. Venetoclax and Obinutuzumab for CLL - Dr. Matt DavidsПодробнее

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLLПодробнее

The latest CLL treatments and therapies with Dr Jan BurgerПодробнее

Dr Dorritie on Unanswered Questions Regarding Upfront Treatment Selection in CLLПодробнее

Frontline therapies for treatment naive CLL patientsПодробнее

Moving towards time-limited treatment in frontline CLLПодробнее

Chronic Lymphocytic Leukemia (CLL): Changes in frontline treatmentПодробнее

What are the current unanswered questions in chronic lymphocytic leukemia (CLL)?Подробнее

Targeted therapies for CLL: new data and unanswered questionsПодробнее

Unanswered questions in aggressive B-cell lymphomaПодробнее

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLLПодробнее

Frontline Treatment Options in CLLПодробнее

Front-line treatment options for CLL | Dr. Jeff Sharman | Oncology Brothers #2023Подробнее

Maintenance and Frontline Therapy in CLLПодробнее

Targeted Therapy Options for Frontline CLLПодробнее

Frontline Therapy in CLL: Combination Strategies and MRDПодробнее

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

Update on CLL/SLL for Newly Diagnosed Patients | LRF WebinarsПодробнее

Unanswered Questions and Conundrums with Frontline NSCLCПодробнее

Frontline treatment for CLL: the changing paradigmПодробнее